It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Recent characterization of spatiotemporal genomic architecture of IDH-wild-type multifocal glioblastomas (M-GBMs) suggests a clinically unobserved common-ancestor (CA) with a less aggressive phenotype, generating highly genetically divergent malignant gliomas/GBMs in distant brain regions. Using serial MRI/3D-reconstruction, whole-genome sequencing and spectral karyotyping-based single-cell phylogenetic tree building, we show two distinct types of tumor evolution in p53-mutant driven mouse models. Malignant gliomas/GBMs grow as a single mass (Type 1) and multifocal masses (Type 2), respectively, despite both exhibiting loss of Pten/chromosome 19 (chr19) and PI3K/Akt activation with sub-tetraploid/4N genomes. Analysis of early biopsied and multi-segment tumor tissues reveals no evidence of less proliferative diploid/2N lesions in Type 1 tumors. Strikingly, CA-derived relatively quiescent tumor precursors with ancestral diploid/2N genomes and normal Pten/chr19 are observed in the subventricular zone (SVZ), but are distantly segregated from multi focal Type 2 tumors. Importantly, PI3K/Akt inhibition by Rictor/mTORC2 deletion blocks distant dispersal, restricting glioma growth in the SVZ.
Recent studies suggest spatial segregation of tumor initiation and manifestation in IDH-WT glioblastomas. Here, the authors use serial MRI/3D-reconstruction, whole-genome sequencing and spectral karyotyping-based single-cell phylogenetic tree building to establish this unique evolutionary mode in a murine model.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Li, Bo 2 ; Li, Wei 3 ; Wang, Yuan 4
; Akgül Seçkin 5
; Treisman, Daniel M 6
; Heist, Kevin A 7 ; Pierce, Brianna R 4 ; Hoff, Benjamin 7 ; Cheng-Ying, Ho 3 ; Ferguson, David O 8 ; Rehemtulla Alnawaz 9 ; Zheng Siyuan 10
; Ross, Brian D 7 ; Li, Jun Z 2
; Zhu, Yuan 11
1 Gilbert Family Neurofibromatosis Institute, Children’s National Hospital, Washington, USA; Center for Cancer and Immunology Research, Children’s National Hospital, Washington, USA; Center for Neuroscience Research, Children’s National Hospital, Washington, USA
2 University of Michigan Medical School, Department of Human Genetics, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
3 Center for Genetic Medicine Research, Children’s National Hospital, Washington, USA (GRID:grid.214458.e)
4 Gilbert Family Neurofibromatosis Institute, Children’s National Hospital, Washington, USA (GRID:grid.214458.e); Center for Cancer and Immunology Research, Children’s National Hospital, Washington, USA (GRID:grid.214458.e); Center for Neuroscience Research, Children’s National Hospital, Washington, USA (GRID:grid.214458.e)
5 Gilbert Family Neurofibromatosis Institute, Children’s National Hospital, Washington, USA (GRID:grid.214458.e); Center for Cancer and Immunology Research, Children’s National Hospital, Washington, USA (GRID:grid.214458.e); Center for Neuroscience Research, Children’s National Hospital, Washington, USA (GRID:grid.214458.e); University of Michigan Medical School, Cellular and Molecular Biology Graduate Program, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); QIMR Berghofer Medical Research Institute, Sid Faithfull Brain Cancer Laboratory, Department of Cell and Molecular Biology, Brisbane, Australia (GRID:grid.1049.c) (ISNI:0000 0001 2294 1395)
6 Gilbert Family Neurofibromatosis Institute, Children’s National Hospital, Washington, USA (GRID:grid.1049.c); Center for Cancer and Immunology Research, Children’s National Hospital, Washington, USA (GRID:grid.1049.c); Center for Neuroscience Research, Children’s National Hospital, Washington, USA (GRID:grid.1049.c); University of Michigan Medical School, Cellular and Molecular Biology Graduate Program, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
7 University of Michigan Medical School, Department of Radiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
8 University of Michigan Medical School, Department of Pathology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
9 University of Michigan Medical School, Department of Radiation Oncology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
10 The University of Texas Health Science Center at San Antonio, Greehey Children’s Cancer Research Institute, San Antonio, USA (GRID:grid.267309.9) (ISNI:0000 0001 0629 5880)
11 Gilbert Family Neurofibromatosis Institute, Children’s National Hospital, Washington, USA (GRID:grid.214458.e); Center for Cancer and Immunology Research, Children’s National Hospital, Washington, USA (GRID:grid.214458.e); Center for Neuroscience Research, Children’s National Hospital, Washington, USA (GRID:grid.214458.e); University of Michigan Medical School, Cellular and Molecular Biology Graduate Program, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); The George Washington University, GW Cancer Center, Washington, USA (GRID:grid.253615.6) (ISNI:0000 0004 1936 9510)




